Jane Street’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.36M | Buy |
221,600
+162,700
| +276% | +$2.46M | ﹤0.01% | 4311 |
|
|
2026
Q1 | $642K | Sell |
58,900
-94,200
| -62% | -$1.18M | ﹤0.01% | 7459 |
|
|
2025
Q4 | $1.98M | Sell |
153,100
-94,300
| -38% | -$1.21M | ﹤0.01% | 4830 |
|
|
2025
Q3 | $3.2M | Buy |
247,400
+16,000
| +7% | +$214K | ﹤0.01% | 4111 |
|
|
2025
Q2 | $4.12M | Buy |
231,400
+16,600
| +8% | +$289K | ﹤0.01% | 3277 |
|
|
2025
Q1 | $3.83M | Sell |
214,800
-269,500
| -56% | -$6.12M | ﹤0.01% | 3324 |
|
|
2024
Q4 | $14.4M | Buy |
484,300
+217,500
| +82% | +$4.6M | ﹤0.01% | 1550 |
|
|
2024
Q3 | $4.17M | Buy |
266,800
+5,800
| +2% | +$105K | ﹤0.01% | 3155 |
|
|
2024
Q2 | $4.47M | Sell |
261,000
-28,900
| -10% | -$508K | ﹤0.01% | 3140 |
|
|
2024
Q1 | $4.53M | Sell |
289,900
-17,000
| -6% | -$250K | ﹤0.01% | 2760 |
|
|
2023
Q4 | $4.58M | Sell |
306,900
-124,600
| -29% | -$1.67M | ﹤0.01% | 2983 |
|
|
2023
Q3 | $6.97M | Sell |
431,500
-58,200
| -12% | -$1.68M | ﹤0.01% | 2192 |
|
|
2023
Q2 | $20.3M | Buy |
489,700
+22,000
| +5% | +$1.37M | 0.01% | 1192 |
|
|
2023
Q1 | $28.1M | Buy |
467,700
+267,500
| +134% | +$21.4M | 0.01% | 795 |
|
|
2022
Q4 | $14.7M | Buy |
200,200
+95,700
| +92% | +$7.2M | 0.01% | 1247 |
|
|
2022
Q3 | $7.94M | Buy |
104,500
+58,600
| +128% | +$4.57M | ﹤0.01% | 1963 |
|
|
2022
Q2 | $3.19M | Sell |
45,900
-37,600
| -45% | -$2.83M | ﹤0.01% | 3347 |
|
|
2022
Q1 | $6.92M | Sell |
83,500
-8,200
| -9% | -$604K | ﹤0.01% | 2533 |
|
|
2021
Q4 | $6.88M | Buy |
91,700
+20,700
| +29% | +$2.08M | ﹤0.01% | 2379 |
|
|
2021
Q3 | $8.25M | Buy |
71,000
+4,400
| +7% | +$665K | ﹤0.01% | 2050 |
|
|
2021
Q2 | $14.8M | Sell |
66,600
-10,600
| -14% | -$2.06M | 0.01% | 1338 |
|
|
2021
Q1 | $10.2M | Sell |
77,200
-125,700
| -62% | -$19.9M | 0.01% | 1534 |
|
|
2020
Q4 | $35.1M | Sell |
202,900
-2,300
| -1% | -$315K | 0.02% | 568 |
|
|
2020
Q3 | $22.8M | Buy |
205,200
+150,300
| +274% | +$12M | 0.01% | 707 |
|
|
2020
Q2 | $3.25M | Sell |
54,900
-53,000
| -49% | -$3.49M | ﹤0.01% | 2392 |
|
|
2020
Q1 | $7.27M | Sell |
107,900
-29,700
| -22% | -$2.35M | 0.01% | 962 |
|
|
2019
Q4 | $11.6M | Sell |
137,600
-67,500
| -33% | -$5.45M | 0.02% | 574 |
|
|
2019
Q3 | $15.3M | Buy |
205,100
+9,000
| +5% | +$720K | 0.03% | 434 |
|
|
2019
Q2 | $12.4M | Buy |
196,100
+96,000
| +96% | +$4.86M | 0.02% | 538 |
|
|
2019
Q1 | $4.82M | Buy |
+100,100
| New | +$4.82M | 0.01% | 1172 |
|
|
2017
Q4 | – | Sell |
-156,100
| Closed | -$3.1M | – | 4996 |
|
|
2017
Q3 | $3.1M | Buy |
156,100
+4,100
| +3% | +$80.6K | 0.01% | 1214 |
|
|
2017
Q2 | $2.63M | Buy |
+152,000
| New | +$1.96M | 0.01% | 1240 |
|
Other funds holding NVCR
SCM
QCM
Jane Street's NVCR Position: Q2 2026 in Review
Jane Street opened a new position in NovoCure (NVCR) in Q2 2026: 81,450 shares worth $1.23M. The stake represents ﹤0.01% of the portfolio and ranks #6096 among its holdings. This is a return to the name: Jane Street previously reported a position in NVCR as recently as Q4 2025.
Jane Street first reported a position in NVCR in Q4 2017 and has held it in 28 quarters since. The position peaked at $21.9M in Q2 2023. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.
- Jane Street held 81,450 shares of NovoCure worth $1.23M as of Q2 2026.
- NovoCure was a new Jane Street position in Q2 2026.
- NovoCure made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #6096 holding.
- Jane Street first reported a position in NovoCure in Q4 2017 and has held it in 28 quarters since.
- Jane Street's NovoCure position peaked at $21.9M in Q2 2023.
- 218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.
Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.